» Articles » PMID: 16445866

Tissue Distribution of a Plasmid DNA Encoding Hsp65 Gene is Dependent on the Dose Administered Through Intramuscular Delivery

Overview
Publisher Biomed Central
Date 2006 Feb 1
PMID 16445866
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

In order to assess a new strategy of DNA vaccine for a more complete understanding of its action in immune response, it is important to determine the in vivo biodistribution fate and antigen expression. In previous studies, our group focused on the prophylactic and therapeutic use of a plasmid DNA encoding the Mycobacterium leprae 65-kDa heat shock protein (Hsp65) and achieved an efficient immune response induction as well as protection against virulent M. tuberculosis challenge. In the present study, we examined in vivo tissue distribution of naked DNA-Hsp65 vaccine, the Hsp65 message, genome integration and methylation status of plasmid DNA. The DNA-Hsp65 was detectable in several tissue types, indicating that DNA-Hsp65 disseminates widely throughout the body. The biodistribution was dose-dependent. In contrast, RT-PCR detected the Hsp65 message for at least 15 days in muscle or liver tissue from immunized mice. We also analyzed the methylation status and integration of the injected plasmid DNA into the host cellular genome. The bacterial methylation pattern persisted for at least 6 months, indicating that the plasmid DNA-Hsp65 does not replicate in mammalian tissue, and Southern blot analysis showed that plasmid DNA was not integrated. These results have important implications for the use of DNA-Hsp65 vaccine in a clinical setting and open new perspectives for DNA vaccines and new considerations about the inoculation site and delivery system.

Citing Articles

Disruptive Technology: CRISPR/Cas-Based Tools and Approaches.

Patsali P, Kleanthous M, Lederer C Mol Diagn Ther. 2019; 23(2):187-200.

PMID: 30945167 PMC: 6469582. DOI: 10.1007/s40291-019-00391-4.


Molecular Adjuvants Based on Plasmids Encoding Protein Aggregation Domains Affect Bone Marrow Niche Homeostasis.

Sabbieti M, Lacava G, Amaroli A, Marchetti L, Censi R, Di Martino P Curr Gene Ther. 2018; 17(5):391-397.

PMID: 29303078 PMC: 6751345. DOI: 10.2174/1566523218666180105122626.


Mycobacterial Hsp65 antigen upregulates the cellular immune response of healthy individuals compared with tuberculosis patients.

Wowk P, Franco L, Fonseca D, Paula M, Vianna E, Wendling A Hum Vaccin Immunother. 2017; 13(5):1040-1050.

PMID: 28059670 PMC: 5443371. DOI: 10.1080/21645515.2016.1264547.


Targeted Collection of Plasmid DNA in Large and Growing Animal Muscles 6 Weeks after DNA Vaccination with and without Electroporation.

Dory D, Le Moigne V, Cariolet R, Beven V, Keranflech A, Jestin A J Immunol Res. 2015; 2015:326825.

PMID: 26380318 PMC: 4561992. DOI: 10.1155/2015/326825.


Delivery strategies for novel vaccine formulations.

Trovato M, Krebs S, Haigwood N, De Berardinis P World J Virol. 2013; 1(1):4-10.

PMID: 24175206 PMC: 3782264. DOI: 10.5501/wjv.v1.i1.4.


References
1.
Tadokoro K, Koizumi Y, Miyagi Y, Kojima Y, Kawamoto S, Hamajima K . Rapid and wide-reaching delivery of HIV-1 env DNA vaccine by intranasal administration. Viral Immunol. 2001; 14(2):159-67. DOI: 10.1089/088282401750234538. View

2.
Vordermeier H, Lowrie D, Hewinson R . Improved immunogenicity of DNA vaccination with mycobacterial HSP65 against bovine tuberculosis by protein boosting. Vet Microbiol. 2003; 93(4):349-59. DOI: 10.1016/s0378-1135(03)00046-4. View

3.
Liu M . Overview of DNA vaccines. Ann N Y Acad Sci. 1995; 772:15-20. DOI: 10.1111/j.1749-6632.1995.tb44727.x. View

4.
Ruberti M, De Melo L, dos Santos S, Brandao I, Soares E, Silva C . Prime-boost vaccination based on DNA and protein-loaded microspheres for tuberculosis prevention. J Drug Target. 2004; 12(4):195-203. DOI: 10.1080/10611860410001723126. View

5.
Mearini G, Nielsen P, Fackelmayer F . Localization and dynamics of small circular DNA in live mammalian nuclei. Nucleic Acids Res. 2004; 32(8):2642-51. PMC: 419472. DOI: 10.1093/nar/gkh587. View